272 related articles for article (PubMed ID: 12937123)
1. Expression of Bcl-2 and Bcl-xL in cutaneous and bone marrow lesions of mastocytosis.
Hartmann K; Artuc M; Baldus SE; Zirbes TK; Hermes B; Thiele J; Mekori YA; Henz BM
Am J Pathol; 2003 Sep; 163(3):819-26. PubMed ID: 12937123
[TBL] [Abstract][Full Text] [Related]
2. Altered apoptosis and cell cycling of mast cells in bone marrow lesions of patients with systemic mastocytosis.
Baldus SE; Zirbes TK; Thiele J; Eming SA; Henz BM; Hartmann K
Haematologica; 2004 Dec; 89(12):1525-7. PubMed ID: 15590405
[TBL] [Abstract][Full Text] [Related]
3. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin?
Lange M; Żawrocki A; Nedoszytko B; Wasąg B; Niedoszytko M; Jassem E; Nowicki R; Żmijewski MA; Biernat W
Int Arch Allergy Immunol; 2014; 165(2):104-10. PubMed ID: 25402852
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L).
Jordan JH; Walchshofer S; Jurecka W; Mosberger I; Sperr WR; Wolff K; Chott A; Bühring HJ; Lechner K; Horny HP; Valent P
Hum Pathol; 2001 May; 32(5):545-52. PubMed ID: 11381374
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2.
Zhang Q; Badell IR; Schwarz EM; Boulukos KE; Yao Z; Boyce BF; Xing L
Arthritis Rheum; 2005 Sep; 52(9):2708-18. PubMed ID: 16142752
[TBL] [Abstract][Full Text] [Related]
6. Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis.
Longley BJ; Morganroth GS; Tyrrell L; Ding TG; Anderson DM; Williams DE; Halaban R
N Engl J Med; 1993 May; 328(18):1302-7. PubMed ID: 7682288
[TBL] [Abstract][Full Text] [Related]
7. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
8. Detection of mi transcription factor (MITF) mRNA in a case of myelodysplastic syndrome and bone marrow mastocytosis.
Wimazal F; Walchshofer S; Baghestanian M; Chott A; Sperr WR; Kopp C; Sillaber C; Semper H; Horny HP; Tröndle U; Födinger M; Schwarzinger I; Lechner K; Valent P
Wien Klin Wochenschr; 1998 Feb; 110(3):79-88. PubMed ID: 9553202
[TBL] [Abstract][Full Text] [Related]
9. Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis.
Taylor ML; Sehgal D; Raffeld M; Obiakor H; Akin C; Mage RG; Metcalfe DD
J Mol Diagn; 2004 Nov; 6(4):335-42. PubMed ID: 15507672
[TBL] [Abstract][Full Text] [Related]
10. Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis.
Hoermann G; Cerny-Reiterer S; Perné A; Klauser M; Hoetzenecker K; Klein K; Müllauer L; Gröger M; Nijman SM; Klepetko W; Valent P; Mayerhofer M
Am J Pathol; 2011 May; 178(5):2344-56. PubMed ID: 21457934
[TBL] [Abstract][Full Text] [Related]
11. Effect of vitamin D3 on the increased expression of Bcl-xL in psoriasis.
Fukuya Y; Higaki M; Higaki Y; Kawashima M
Arch Dermatol Res; 2002 Feb; 293(12):620-5. PubMed ID: 11875645
[TBL] [Abstract][Full Text] [Related]
12. Mast cells in systemic mastocytosis have distinctly brighter CD45 expression by flow cytometry.
Chisholm KM; Merker JD; Gotlib JR; Gitana G; Lefterova M; Zehnder JL; George TI; Arber DA; Ohgami RS
Am J Clin Pathol; 2015 Apr; 143(4):527-34. PubMed ID: 25780004
[TBL] [Abstract][Full Text] [Related]
13. Tryptase detection in bone-marrow blood: a new diagnostic tool in systemic mastocytosis.
Proelss J; Wenzel J; Ko Y; Bieber T; Bauer R
J Am Acad Dermatol; 2007 Mar; 56(3):453-7. PubMed ID: 17317486
[TBL] [Abstract][Full Text] [Related]
14. CD25 expression on cutaneous mast cells from adult patients presenting with urticaria pigmentosa is predictive of systemic mastocytosis.
Hollmann TJ; Brenn T; Hornick JL
Am J Surg Pathol; 2008 Jan; 32(1):139-45. PubMed ID: 18162781
[TBL] [Abstract][Full Text] [Related]
15. Mastocytosis and related disorders.
Chiu A; Orazi A
Semin Diagn Pathol; 2012 Feb; 29(1):19-30. PubMed ID: 22372203
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2 and Bcl-xL in peroxide-resistant A549 and U87MG cells.
Bojes HK; Suresh PK; Mills EM; Spitz DR; Sim JE; Kehrer JP
Toxicol Sci; 1998 Apr; 42(2):109-16. PubMed ID: 9579023
[TBL] [Abstract][Full Text] [Related]
17. Transglutaminase 2 expressed in mast cells recruited into skin or bone marrow induces the development of pediatric mastocytosis.
Ahn YM; Hong GU; Kim SH; Lee HJ; Baek HS; Kim MN; Park KY; Ro JY
Pediatr Allergy Immunol; 2015 Aug; 26(5):438-45. PubMed ID: 25952500
[TBL] [Abstract][Full Text] [Related]
18. STAT3 mRNA and protein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferation.
Lassmann S; Schuster I; Walch A; Göbel H; Jütting U; Makowiec F; Hopt U; Werner M
J Clin Pathol; 2007 Feb; 60(2):173-9. PubMed ID: 17264243
[TBL] [Abstract][Full Text] [Related]
19. Clonality and molecular pathogenesis of mastocytosis.
Akin C
Acta Haematol; 2005; 114(1):61-9. PubMed ID: 15995326
[TBL] [Abstract][Full Text] [Related]
20. Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-xL and bak expression.
Liu QY; Stein CA
Clin Cancer Res; 1997 Nov; 3(11):2039-46. PubMed ID: 9815595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
